SCHEMBL311762

SCHEMBL311762

FC(F)(F)Oc1cccc(-c2c[nH]c(C3CCNCC3)n2)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLAT P00750 2/20 0.48
TYRO3 Q06418 1/20 0.46
XDH P47989 1/20 0.46
PDE10A Q9Y233 1/20 0.43
PIM1 P11309 6/20 0.43
MEN1 O00255 1/20 0.42
POLB P06746 1/20 0.42
KMT2A Q03164 1/20 0.42
DYRK1A Q13627 1/20 0.41
CTSS P25774 2/20 0.41
CTSK P43235 2/20 0.41
CTSL P07711 1/20 0.41
CTSB P07858 1/20 0.41
PIM3 Q86V86 2/20 0.40
PIM2 Q9P1W9 2/20 0.40
PDE4A P27815 1/20 0.40
PDE4B Q07343 1/20 0.40
PDE4C Q08493 1/20 0.40
PDE4D Q08499 1/20 0.40
HTR2C P28335 3/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL311523 0.81 MEN1 (0.62) PLATMEN1POLBKMT2AHTR2C
SCHEMBL90992 0.78 TYRO3 (0.40) TYRO3XDHPDE10APIM1PIM2
SCHEMBL17065185 0.78 PLAT (0.48) PLATTYRO3XDHPIM1CTSS
SCHEMBL312409 0.78 SLC18A3 (0.50) MEN1KMT2AHTR2CKCNH2
SCHEMBL27776222 0.77 GABRA1 (0.46) PLAT
SCHEMBL474804 0.77 XDH (0.67) TYRO3XDHPDE10ADYRK1ACTSS
Hydrochloric Acid SCHEMBL1653372 0.76 SLC18A3 (0.49) MEN1KMT2AHTR2CKCNH2
SCHEMBL4943023 0.76 HTR2C (0.65) PLATPIM1CTSSCTSKCTSL
Hydrochloric Acid SCHEMBL311386 0.76 SLC18A3 (0.49) MEN1KMT2AHTR2CKCNH2
Hydrochloric Acid SCHEMBL311446 0.76 GABRA1 (0.45) PLATHTR2C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101679439-B P70S 6 kinase inhibitors LILLY CO ELI 2013-09-11 CN disclosed
US-20120071490-A1 P70 S6 KINASE INHIBITORS ELI LILLY AND COMPANY (US) 2012-03-22 US disclosed
US-8093383-B2 P70 S6 kinase inhibitors ELI LILLY AND COMPANY (US) 2012-01-10 US disclosed
CN-101679439-A P70S 6 kinase inhibitors LILLY CO ELI 2010-03-24 CN disclosed
EP-2148880-A1 P70 S6 KINASE INHIBITORS ELI LILLY AND COMPANY (US) 2010-02-03 EP disclosed
US-20090163714-A1 P70 S6 KINASE INHIBITORS ELI LILLY AND COMPANY 2009-06-25 US disclosed
WO-2008140947-A1 P70 S6 KINASE INHIBITORS ELI LILLY AND COMPANY (US) 2008-11-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090163714-A1 P70 S6 KINASE INHIBITORS RPS6KA6, RPS6KA1, RPS6KA2 PLAT 4515/4885TYRO3 2124/4885XDH 4788/4885
US-20120071490-A1 P70 S6 KINASE INHIBITORS RPS6KA6, RPS6KA1, RPS6KA2 PLAT 4515/4885TYRO3 2124/4885XDH 4788/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.